SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
Ann R. Falsey, Robert W. Frenck, Edward E. Walsh, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Ruth Bailey, Kena A. Swanson, Xia Xu, Kenneth Koury, Warren V. Kalina, David Cooper, Jing Zou, Xuping Xie, Hongjie Xia, Özlem Türeci, Eleni Lagkadinou, Kristin Tompkins, Pei‐Yong Shi, Kathrin U. Jansen, Uğur Şahin, Philip R. Dormitzer, William C. Gruber
Abstract
Immune Response to a Third Dose of BNT162b2 A third dose of the BNT162b2 vaccine was administered to 23 volunteers 8 to 9 months after the second dose, and the immune response was assessed. Local r...
Topics & Concepts
NeutralizationImmune systemMedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakImmunologyVirusInternal medicineInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studiesViral gastroenteritis research and epidemiology